PlainRecalls
FDA Drug Critical Class I Terminated

Topotecan Injection 4 mg/4mL (1 mg/mL), Single-Dose vial, Teva Pharmaceuticals USA, Inc. North Whales, PA 19454, Carton NDC# 0703-4714-01, Vial NDC# 0703-4714-71

Reported: July 14, 2021 Initiated: June 18, 2021 #D-0661-2021

Product Description

Topotecan Injection 4 mg/4mL (1 mg/mL), Single-Dose vial, Teva Pharmaceuticals USA, Inc. North Whales, PA 19454, Carton NDC# 0703-4714-01, Vial NDC# 0703-4714-71

Reason for Recall

Presence of Particulate Matter: Complaint received of a glass particle observed inside the vial. The vial was returned to Teva for further analysis where two other particulates were found and identified as one (1) grey silicone particle and one (1) translucent, colorless cotton fiber.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
10,425 vials
Distribution
Distributed Nationwide in the USA
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
Topotecan Injection 4 mg/4mL (1 mg/mL), Single-Dose vial, Teva Pharmaceuticals USA, Inc. North Whales, PA 19454, Carton NDC# 0703-4714-01, Vial NDC# 0703-4714-71. Recalled by Teva Pharmaceuticals USA. Units affected: 10,425 vials.
Why was this product recalled?
Presence of Particulate Matter: Complaint received of a glass particle observed inside the vial. The vial was returned to Teva for further analysis where two other particulates were found and identified as one (1) grey silicone particle and one (1) translucent, colorless cotton fiber.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 14, 2021. Severity: Critical. Recall number: D-0661-2021.